PDCD1 and hepatocellular carcinoma: Among immunotherapies, the success of ICIs therapy targeting PD-1, PD- L1, and CTLA-4 in solid and hematological tumors has shifted more attention to its potential in advanced HCC (Table 1 and Figure 2).